Isis Oral TNF-Alpha Inhibitor For Rheumatoid Arthritis To Enter Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Isis is ramping up efforts to develop an oral tumor necrosis factor alpha inhibitor for rheumatoid arthritis, with plans to begin a Phase II trial of its oral anti-TNF antisense agent ISIS 104838 in mid-2005.